Inflammatory Bowel Disease: Role of the Primary Care Provider

On-Demand Webinar   |   Aug. 23, 2018


IBD_8.20118 (1).png



CME Participation Waiver *
By registering for the webinar, you are confirming that you agree to the waiver available at the bottom of this page.


Assistant Professor, Department of Internal Medicine; Medical Director, OSU Inflammatory Bowel Disease Center; Abercrombie & Fitch Endowed Chair in Inflammatory Bowel Disease; Division of Gastroenterology, Hepatology and Nutrition, The Ohio State University Wexner Medical Center


Dr. Anita Afzali is an Assistant Professor of Clinical Medicine and a Gastroenterologist that specializes in Inflammatory Bowel Disease (IBD) at The Ohio State University Wexner Medical Center. She is the Medical Director of the OSU Inflammatory Bowel Disease Center and holds the Abercrombie & Fitch Endowed Chair in Inflammatory Bowel Disease.

She received her medical degree from the University of Washington School of Medicine. She then completed her Internal Medicine residency and a Gastroenterology fellowship at the University of Washington in Seattle, WA. While in fellowship, Dr. Afzali worked in outcomes research and epidemiology, and also graduated with a Master’s in Public Health (MPH). Her sub-specialty training includes a one-year advanced IBD fellowship at the University of Washington, prior to becoming faculty at UW Medicine. While practicing at the University of Washington – Harborview Medical Center, Dr. Afzali served as the Director of the IBD Program and Associate Medical Director of the UW- HMC Gastroenterology Clinics.

Her research interests include clinical outcomes and risks of IBD therapy, pharmacoepidemiology, pharmacoeconomics, as well as the impact of race/ethnicity in IBD, pediatric-to-adult transition, and women of childbearing age with IBD. In collaboration with Seattle Children’s Hospital, she has developed the first Pediatric to Adult IBD Transition Clinic in the Northwest. She has had extensive peer-reviewed publications, is an invited lecturer on national and international programs, and serves as an expert thought leader on several national and international advisory boards and panels.

Dr. Afzali serves on several committees including a committee member of the Crohn’s Colitis National Professional Education Committee (NPEC) and the Clinical Research Alliance (CRA) in IBD. She was also an invited clinical faculty for the Advances in Inflammatory Bowel Disease (AIBD). Fellowship to the American College of Gastroenterology (ACG) was recently awarded to Dr. Afzali for her significant professional achievement and superior competence within the field of gastroenterology and inflammatory bowel disease.



Inflammatory Bowel Disease (IBD) affects 1.3% (~3 million) of US adults (either Crohn's disease or ulcerative colitis). This percentage of diagnosed patients with IBD increased from 0.9% over the past 15 years. Patients with IBD frequently have recurrent symptoms with considerable morbidity. IBD treatment generally involves medical treatment including aminosalicylates, corticosteroids, immunomodulators, and biologics. If necessary, the damaged parts of the gastrointestinal tract can be removed through surgical treatment. In this webinar, Dr. Anita Afzali MD, MPH, FACG, will review the basics of IBD, including epidemiology and pathophysiology; present treatment strategies and therapeutic disease target goals; and share strategies on a health maintenance plan and practice preventative care for the IBD patient.


This lecture will be conducted as a one-hour live webinar. Registration is free. Participants will submit a survey at the end of the session to claim CME credit.


  • J. Nwando Olayiwola, MD, MPH, FAAFP

  • Anna Potapov, MD, MPH, MBA

  • Marc E. Walker, MD, MBA

  • Pooja Mittal, DO



By the end of the event, participants should:

  1. Review Inflammatory Bowel Disease (IBD) 101, including epidemiology and pathophysiology.

  2. Understand treatment strategies and therapeutic disease target goals.

  3. Develop a health maintenance plan and practice preventative care for the IBD patient.


This Live series activity, Optimizing Management of Common Specialty Conditions in the Primary Care Setting, from 07/01/2018 - 07/01/2019, has been reviewed and is acceptable for credit by the American Academy of Family Physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Each webinar in the series is approved for 1.0 AAFP Prescribed credits unless otherwise noted. 

AMA/AAFP Equivalency: AAFP Prescribed credit is accepted by the American Medical Association as equivalent to AMA PRA Category 1 credit(s)™ toward the AMA Physician’s Recognition Award. When applying for the AMA PRA, Prescribed credit earned must be reported as Prescribed, not as Category 1. 

This Live series activity is eligible for Continuing Education credit from the American Association of Physician Assistants (AAPA) and the American Association of Nurse Practitioners (AANP). Physician Assistants (PAs) and Nurse Practitioners (NPs) may claim AMA PRA Category 1 equivalent credits per webinar based on their participation.